| Name | Title | Contact Details |
|---|
Learn how to invest in real estate with educational resources, evaluate properties using expert tools, and connect with other investors. Sign up now!
Global consumer insights for Investors and Companies designed to answer complex questions on consumer behavior.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
SA Technologies Inc is a Santa Clara, CA-based company in the Software & Internet sector.
We work to transform the lives of kids and young adults by expanding access to technology and information, and teaching them 21st century skills.